Lesson plan

Synapsinostat

Synapsinostat, also known as CN13, is a histone deacetylase (HDAC) inhibitor and possible cognitive enhancer. It potently inhibits the class I HDAC1, HDAC2, and HDAC3, with values of 39 nM, 41 nM, and 100 nM, respectively, whereas other HDACs were not assessed. The drug has been found to potently promote synaptogenesis in vitro. Synapsinostat was first described in the scientific literature by 2009. Subsequently, other improved analogues acting as HDAC inhibitors such as crebinostat and neurinostat, which show much greater potency, were described.

Back to article

Article summary

Synapsinostat, also known as CN13, is a histone deacetylase (HDAC) inhibitor and possible cognitive enhancer. It potently inhibits the class I HDAC1, HDAC2, and HDAC3, with values of 39 nM, 41 nM, and 100 nM, respectively, whereas other HDACs were not assessed. The drug has been found to potently promote synaptogenesis in vitro. Synapsinostat was first described in the scientific literature by 2009. Subsequently, other improved analogues acting as HDAC inhibitors such as crebinostat and neurinostat, which show much greater potency, were described.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.